Intellia Therapeutics has crossed the line that separates a clinical-stage CRISPR platform from a near-commercial rare-disease company. The Food and Drug Administration accepted the biologics license application for lonvoguran ziclumeran in hereditary angioedema and granted Priority Review, with no advisory committee currently planned. That filing rests on a Phase 3 result published in the New England Journal of Medicine, not on a biomarker story. The equity debate is no longer whether in vivo editing can produce a registrational dataset. It is whether a one-time infusion into a crowded prophylaxis market, plus a still-watched ATTR program, justifies a platform multiple after a liver-safety interruption that already cost the second asset a winter of enrollment. Cash of $628 million at mid-year is guided to fund operations into 2028 before any product sales.
The second program is the larger commercial prize and the scar. MAGNITUDE, the roughly twelve-hundred-patient cardiomyopathy trial of nexiguran ziclumeran, spent last autumn on clinical hold after a grade-four liver event and a subsequent patient death. Both MAGNITUDE and MAGNITUDE-2 are enrolling again after the agency lifted the holds, with extra monitoring, steroid guidance, and tighter exclusion rules. More than 650 patients sit in the cardiomyopathy study. Regeneron still owns about a quarter of worldwide ATTR economics. The market can treat lonvo-z as a de-risked rare-disease launch and still refuse to pay for nex-z as if the hold never happened.
The April follow-on added about $195 million of net proceeds. An OrbiMed senior facility later funded a first draw of $75 million against a larger milestone stack. Mid-year cash still only barely exceeds year-end after a $200 million first-half operating cash burn. General and administrative spend is already rising into the commercial build. The question for the next several quarters is whether Priority Review converts into a clean label before MAGNITUDE's residual liver signal, or the launch cost stack, forces another trip to the equity window.